• Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
  • Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
  • Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
  • Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
  • Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
  • Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin

Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin

Powder: Yes
Customized: Non-Customized
Certification: GMP, ISO 9001, USP, BP
Suitable for: Elderly, Adult
State: Solid
Purity: >99%
Samples:
US$ 1/gram 1 gram(Min.Order)
| Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Trading Company

Basic Info.

Model NO.
TY-02AL
CAS No.
72496-41-4
Appearance
White Powder
Einecs
616-396-9
Assay
99%
Shelf
2 Years
Transport Package
25kg/Drum1g, 50g, 500g, 1kg, 10kg, 100kg, 200kg
Specification
25kg/drum
Trademark
tongyon
Origin
China
Production Capacity
5000kg/Month

Product Description

Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin

Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin
 
Product name Pirarubicin
CAS 72496-41-4
Appearance white powder
Assay 99%
Storage Cool and Protect from light


Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin

Product Name:Pirarubicin
CAS:72496-41-4
MF:C32H37NO12
MW:627.64
EINECS:
Mol File:72496-41-4.mol 
Melting point:188-192°C (dec.)
alpha D25 +175 ±25° (c = 0.2 in CHCl3)
Boiling point:834.7±65.0 °C(Predicted)
Density 1.51±0.1 g/cm3(Predicted)
storage temp. 2-8°C
solubility ethanol: soluble25mg/mL
pka7.35±0.60(Predicted)
form powder




Factory Supply Raw Material API CAS 72496-41-4 Pirarubicin


Description
Pirarubicin is a new anthracycline anticancer agent structurally related to doxorubicin. In acute leukemia, non-Hodgkin's lymphoma, breast and ovariail carcinoma, pirarubicin is reportedly superior to doxorubicin and better tolerated. Its major side-effect appears to be myelosuppression, mainly in the form of leucopenia, which is potentially dose-limiting.
Chemical PropertiesRed Solid
UsesStructural analog of Doxorubicin. Antineoplastic


GuangZhou TongYi biochemistry technology Co., Ltd is a company specializing in active pharmaceutical ingredient
(API), biology, plant extracts, chemical raw materials, fine chemicals, pharmaceutical intermediates, cosmetics raw
material. Our company has always adhered to the company phi
osophy of integrity, professionalism, quality first, and
customer service. With the efforts of all the company's employees, it has established long-term
and stable cooperative relations with many domestic and foreign customers, and won the unanimous trust of domestic
and foreign customers. With good comments, our company have made great progress.


Our company takes pioneering and innovative, high-quality and efficient as the code of conduct, and strives to provide
customers with efficient services,
high-quality products, and reasonable prices. We have established a customer demand-oriented, flexible, diverse and customizable service according to the different needs of different customers. Mode, and ultimately achieve the goal of
win-win.


Our company focuses on the future and the world, and will continue to devote itself to technological progress and the
development of new products in the future, hoping to work hand in hand with new and old friends at home and abroad
to create a better future.


Factory Supply Raw Material API CAS 72496-41-4 PirarubicinFactory Supply Raw Material API CAS 72496-41-4 PirarubicinFactory Supply Raw Material API CAS 72496-41-4 PirarubicinFactory Supply Raw Material API CAS 72496-41-4 PirarubicinFactory Supply Raw Material API CAS 72496-41-4 Pirarubicin

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now

You Might Also Like

Diamond Member Since 2021

Suppliers with verified business licenses

Trading Company
Number of Employees
2
Year of Establishment
2017-08-08